|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 271.06 Million
|
|
Market Size (2030)
|
USD 390.11 Million
|
|
CAGR (2025-2030)
|
6.37%
|
|
Fastest Growing Segment
|
Quantitative PCR
|
|
Largest Market
|
South India
|
Market Overview
Polymerase Chain Reaction (PCR)
Devices Market in was valued at USD 271.06 Million in 2024 and is expected to
reach USD 390.11 Million by 2030 with a CAGR of 6.37% during the forecast
period.
Growth is driven by advancements in molecular diagnostics and expanding applications across clinical diagnostics, research, forensic science, and biotechnology. PCR devices are essential for DNA amplification, detecting genetic mutations, identifying infectious diseases, and conducting genetic research.
Rising prevalence of infectious diseases, including COVID-19, tuberculosis, HIV, and hepatitis B and C, India recorded an estimated 35 million hepatitis cases in 2022 has boosted demand for rapid, accurate diagnostics. Government initiatives to strengthen healthcare infrastructure and fund research further support adoption. Technological innovations like real-time PCR (qPCR), digital PCR, automated systems, and user-friendly interfaces have improved sensitivity, specificity, throughput, and operational efficiency.
The market includes multinational and domestic players competing through collaborations, mergers, and portfolio expansion. Increasing awareness of personalized medicine and demand for genetic testing offer growth opportunities. Challenges such as high device costs and the need for trained personnel exist, but efforts to develop cost-effective solutions and training programs are expected to sustain market growth.
Key Market Drivers
Increasing
Prevalence of Infectious Diseases
The India Polymerase Chain Reaction devices market is being propelled by sustained diagnostic demand from infectious diseases and the scaling of molecular testing capacity across public and private healthcare settings. For instance, the Government of India reports record tuberculosis case notifications of 25.5 lakh in 2023 and 26.07 lakh in 2024, and the India TB Report 2024 highlights 63,939 multidrug-resistant TB cases diagnosed, underscoring why rapid molecular platforms are increasingly embedded in routine TB detection and drug-resistance screening. Seasonal and outbreak-prone vector-borne diseases further reinforce the need for rapid, accurate testing, with the National Centre for Vector Borne Diseases Control reporting 2,89,235 dengue cases and 485 deaths in 2023 and 2,33,519 cases and 297 deaths in 2024.
In parallel, malaria surveillance and elimination efforts continue to require reliable diagnostics, with the Ministry of Health and Family Welfare reporting 2,27,564 malaria cases and 83 deaths in 2023. The COVID-19 experience also expanded India’s molecular diagnostics backbone, with the ICMR COVID testing portal showing 9,548 labs and 25,319 collection centres as of May 27, 2024, supporting ongoing PCR device adoption through wider lab networks, higher-throughput workflows, and public health testing programs.
Technological
Advancements and Innovations
Technological advancements are key drivers of growth in the India PCR devices market. PCR has evolved with innovations like real-time PCR (qPCR), digital PCR (dPCR), and NGS-based PCR, offering higher sensitivity, specificity, and speed for accurate molecular diagnostics. Real-time PCR quantifies DNA or RNA during amplification, improving diagnostic reliability. Digital PCR partitions samples into thousands of droplets, enabling precise detection of rare mutations. NGS-based PCR combines sequencing with amplification, expanding applications in genomics and personalized medicine.
Automated PCR systems streamline workflows, reduce human error, and increase throughput, while advanced software and robotics enhance consistency and efficiency. Miniaturization and portable, point-of-care devices extend PCR use to remote or resource-limited areas, allowing rapid on-site diagnostics critical for disease management and outbreak control.
Continuous R&D investment drives next-generation PCR devices that are faster, user-friendly, and capable of multiplexing to detect multiple targets simultaneously. These innovations broaden PCR applications across clinical diagnostics, infectious disease detection, oncology, and genetic testing, reinforcing its central role in India’s healthcare and research sectors.
Growing
Applications in Oncology
The expanding use of PCR in oncology is driving growth in India’s PCR devices market. PCR enables early cancer detection, prognosis, treatment monitoring, and identification of genetic mutations, supporting timely interventions for cancers like breast, lung, and colorectal. Its high sensitivity and specificity allow detection before symptoms appear, improving patient outcomes.
Liquid biopsy techniques using PCR detect circulating tumor DNA (ctDNA) non-invasively, reducing risks of surgical biopsies. They support ongoing monitoring of disease progression, treatment response, and emerging resistance, enabling personalized therapy adjustments. This approach improves management of minimal residual disease and tailors treatment plans to individual genetic profiles.
Rising cancer prevalence, aging population, lifestyle changes, and increased awareness of early diagnosis are fueling demand for PCR devices in oncology. Public and private healthcare adoption, along with personalized medicine initiatives, underscores PCR’s role in guiding targeted therapies and immunotherapies, enhancing treatment efficacy, and minimizing side effects.
Download Free Sample Report
Key Market Challenges
High
Cost of PCR Devices and Consumables
One of the primary challenges in the India Polymerase
Chain Reaction (PCR) devices market is the high cost associated with PCR
machines and related consumables, such as reagents, primers, and kits. The
initial investment required to purchase PCR machines can be substantial, often exceeding the budgetary capacity of many healthcare facilities. This
financial barrier is particularly pronounced in rural and semi-urban areas,
where healthcare infrastructure is often underdeveloped, and resources are limited.
In these settings, accurate, timely diagnostic tools are critical for effective disease management, yet the high costs of PCR technology can severely limit access to these essential services.
The expensive nature of PCR technology not only
affects larger hospitals but also deters smaller laboratories and clinics from
adopting these advanced diagnostic devices. Many of these facilities operate on
tight budgets and may prioritize essential services over costly investments in
molecular diagnostics. This reluctance to invest in PCR technology leads to
significant disparities in healthcare access across different regions. While
urban areas may have access to cutting-edge diagnostic tools, rural regions
often rely on outdated methods that lack the precision and reliability of PCR
testing.
The costs associated with consumables can
accumulate over time, making ongoing operations financially burdensome for
facilities that do choose to implement PCR testing. Reagents, primers, and kits
often have expiration dates and require regular replenishment, which adds to overall costs.
Technical
Complexity and Training Requirements
PCR technology, despite its
effectiveness, is complex and requires skilled personnel for proper execution
and interpretation of results. This technical complexity poses a significant
challenge for the Polymerase Chain Reaction (PCR) devices market in India,
particularly in a healthcare landscape where resources and expertise may be
limited. The successful implementation of PCR testing requires not only a thorough understanding of the principles of molecular biology but also proficiency with sophisticated laboratory equipment.
In India, there is often a shortage of
qualified technicians proficient in advanced molecular techniques, which can
lead to variations in testing quality and reliability. Insufficient training for laboratory personnel can lead to inconsistent results and errors, undermining the credibility of PCR testing. When technicians
are not adequately trained, the risk of contamination, sample mishandling, and
misinterpretation of results increases, making it harder to diagnose and manage diseases effectively. Consequently, this can erode healthcare
providers' confidence in PCR testing, which may deter them from fully
integrating this valuable technology into their practices.
To address this
issue, it is crucial to develop robust training initiatives that equip
laboratory personnel with the necessary skills to operate PCR devices
effectively. Implementing comprehensive training programs that combine theoretical knowledge with hands-on experience can help bridge the skills gap in
the workforce. Collaboration between academic institutions, healthcare
organizations, and industry stakeholders can facilitate the creation of
standardized training curricula tailored to the needs of different
laboratories.
Key Market Trends
Increasing
Prevalence of Infectious Diseases
The India PCR devices market is growing rapidly, driven by the rising prevalence of infectious diseases such as tuberculosis, dengue, malaria, and COVID-19. PCR technology enables rapid and precise pathogen detection, including in asymptomatic individuals, making it essential for outbreak management and public health programs.
In March 2024, CoSara Diagnostics, a joint venture of Co-Diagnostics, received CDSCO approval to manufacture its SARAPLEX Influenza Multiplex Test Kit for detecting Influenza A and B, reflecting the market’s emphasis on rapid, reliable diagnostics. Government initiatives, widespread testing campaigns, and partnerships with private healthcare providers are further boosting PCR adoption across the country.
Tuberculosis remains a critical driver, with India accounting for a large share of global cases. PCR allows rapid identification of drug-resistant TB strains, enabling targeted treatment and reduced transmission. Seasonal vector-borne diseases like dengue and malaria also increase demand for timely molecular diagnostics. The COVID-19 pandemic amplified the need for PCR testing, demonstrating its scalability and reliability in large-scale health crises.
Overall, the increasing burden of infectious diseases, integration of PCR in public health strategies, and the technology’s proven accuracy ensure sustained demand. PCR devices remain a cornerstone of India’s healthcare infrastructure, supporting disease detection, outbreak control, and long-term public health management.
Increasing
Use in Genetic Testing
The India PCR devices market is being driven by growing applications in genetic testing, which is increasingly important for diagnosing inherited disorders, identifying genetic risks, and guiding reproductive decisions. PCR allows precise amplification and detection of DNA sequences, supporting carrier screening, prenatal testing, newborn screening, and pharmacogenomics.
Carrier screening uses PCR to detect gene variants, helping parents assess the risk of passing on genetic disorders. Prenatal testing identifies fetal genetic abnormalities, enabling early intervention, while newborn screening detects treatable disorders shortly after birth. Pharmacogenomics leverages PCR to analyze genetic variations affecting drug response, allowing personalized medication regimens.
Rising awareness of genetic health, coupled with increasing prevalence of disorders like thalassemia, cystic fibrosis, and sickle cell anemia, has boosted demand for PCR-based genetic testing. Advanced techniques such as multiplex PCR, which detects multiple targets simultaneously, and quantitative PCR, which measures DNA or RNA precisely, enhance efficiency, reduce costs, and improve accuracy.
Government initiatives promoting genetic testing and personalized medicine further encourage adoption. As genetic testing becomes more accessible and integrated into routine clinical practice, PCR devices are expected to maintain strong growth, supporting proactive healthcare and improved patient outcomes across India.
Segmental Insights
Type Insights
Based on
the Type, In the India Polymerase Chain Reaction (PCR) devices market,
quantitative PCR (qPCR) is currently dominating the type of segment. This
dominance can be attributed to several key factors that highlight its
advantages over digital PCR (dPCR) in clinical and research applications. qPCR is a robust, established method for quantifying nucleic acids, making it highly versatile for applications such as gene expression
analysis, pathogen detection, and genetic variation studies. Its ability to
provide real-time data during amplification enables researchers and
clinicians to obtain rapid results, which is crucial in time-sensitive
scenarios such as infectious disease diagnostics.
qPCR is
more widely adopted because it is compatible with existing laboratory workflows
and equipment. Many laboratories already use qPCR systems, making it easier for them to integrate this technology without significant
additional investment in new infrastructure. The cost-effectiveness of qPCR
contributes to its popularity. Compared to dPCR, which requires more
specialized equipment and often incurs higher operational costs, qPCR devices
are generally more affordable and accessible for a broader range of healthcare
facilities and research institutions.
Download Free Sample Report
Regional Insights
In the
India Polymerase Chain Reaction (PCR) devices market, the south India region dominated due to several key factors that drive its growth and
adoption of molecular diagnostics. This region is home to some of the country’s
leading healthcare institutions, research centers, and biotechnology companies, all of which significantly drive demand for advanced PCR technology. States
such as Tamil Nadu, Karnataka, and Andhra Pradesh have established a strong
healthcare infrastructure, with numerous diagnostic laboratories and hospitals
that utilize PCR devices for various applications, including infectious disease
detection and genetic testing. The presence of prominent research institutions
and universities in southern India also fosters innovation and development in
molecular biology, further bolstering the region's position in the PCR market.
The increasing prevalence of infectious diseases and genetic disorders in
southern India has heightened the need for accurate and timely diagnostic
solutions. Public health initiatives and government support for improving
healthcare access and quality in this region have also played a crucial role in
driving the adoption of PCR technology. The growing awareness
among healthcare providers and patients about the benefits of molecular
diagnostics has led to increased utilization of PCR testing services. As a
result, the southern region continues to dominate the India PCR devices market,
positioning itself as a hub for advanced diagnostics and healthcare solutions.
Recent Developments
- In November 2025, Co-Diagnostics announced it engaged Maxim Group to pursue a SPAC transaction for its Indian JV CoSara, including the possibility of a merger with a SPAC or similar listed entity.
- In July 2025, Avacta announced an agreement to sell Coris Bioconcept to India’s 3B BlackBio Dx for an upfront £2.15 million plus an earn-out of up to £0.615 million (subject to customary closing conditions), strengthening 3B BlackBio’s IVD portfolio relevant to molecular diagnostics workflows.
- In February 2023, Thermo Fisher Scientific announced the launch of its
real-time PCR kits for detecting infectious diseases in India. The Applied
Biosystems TaqPath PCR kits are specifically designed to ensure confidence
and reliability in diagnostic development and testing. These kits target a
range of infectious diseases, including Multi-Drug-Resistant Tuberculosis (MTB
MDR), M. tuberculosis complex (MTB), Hepatitis B Virus (HBV), Hepatitis C Virus
(HCV), Human Immunodeficiency Virus (HIV), and genetic analysis (HLA B27). The
Central Drugs Standard Control Organization (CDSCO) has granted licensing rights
for these kits, which will be produced in India in collaboration with Mylab
Discovery Solutions, a leading healthcare provider in the country. This
partnership underscores Thermo Fisher Scientific’s commitment to enhancing
diagnostic capabilities in India.
Key Market Players
|
By Type
|
By End User
|
By Region
|
- Quantitative PCR
- Digital PCR
|
- Hospitals & Clinics
- Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Others
|
|
Report Scope:
In this report, the India Polymerase Chain Reaction
(PCR) Devices Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- India Polymerase Chain Reaction (PCR) Devices
Market, By Type:
o
Quantitative PCR
o
Digital PCR
- India Polymerase Chain Reaction (PCR) Devices
Market, By End
User:
o
Hospitals & Clinics
o
Diagnostic Laboratories
o
Pharmaceutical & Biotechnology Companies
o
Others
- India Polymerase Chain Reaction (PCR) Devices
Market, By
Region:
o
North
o
South
o
West
o
East
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the India Polymerase Chain Reaction
(PCR) Devices Market.
Available Customizations:
India Polymerase Chain Reaction (PCR) Devices Market report with the given market data,
TechSci Research offers customizations according to a company's specific
needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
India Polymerase Chain
Reaction (PCR) Devices Market is an upcoming report to be
released soon. If you wish an early delivery of this report or want to confirm
the date of release, please contact us at [email protected]